Genetic model of selective COX2 inhibition reveals novel heterodimer signaling

Nature Medicine

Volumn 12, Issue 6, 2006, Pages 699-704

  Yu, Ying ^a   Fan, Jinjin ^a   Chen, Xin Sheng ^a,d   Wang, Dairong ^a   Klein Szanto, Andres J ^b   Campbell, Robert L ^c   FitzGerald, Garret A ^a   Funk, Colin D ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENZYME; HETERODIMER; PROSTAGLANDIN H SYNTHASE 1; PROSTAGLANDIN H SYNTHASE 2; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE TARGETING; GENETIC MODEL; MOUSE; NEWBORN; NONHUMAN; PATENT DUCTUS ARTERIOSUS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASE SEQUENCE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIMERIZATION; DUCTUS ARTERIOSUS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, GENETIC; MODELS, MOLECULAR; POINT MUTATION; PROTEIN STRUCTURE, QUATERNARY; SIGNAL TRANSDUCTION;

EID: 33744986028     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1412     Document Type: Article

References (30)

1. FitzGerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
2. Grosser, T., Fries, S. & FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
3. Bresalier, R.S. et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
4. Solomon, S.D. et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
5. Nussmeier, N.A. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081-1091 (2005).
6. Smith, W.L., DeWitt, D.L. & Garavito, R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
7. Crofford, L.J. et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 β, phorbol ester, and corticosteroids. J. Clin. Invest. 93, 1095-1101 (1994).
8. Schonbeck, U., Sukhova, G.K., Graber, P., Coulter, S. & Libby, P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281-1291 (1999).
9. Loftin, C.D. et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 98, 1059-1064 (2001).
10. Loftin, C.D., Trivedi, D.B. & Langenbach, R. Cyclooxygenase-1- selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J. Clin. Invest. 110, 549-557 (2002).
11. Picot, D., Loll, P.J. & Garavito, R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367, 243-249 (1994).
12. Kurumbail, R.G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648 (1996).
13. Malkowski, M.G., Ginell, S.L., Smith, W.L. & Garavito, R.M. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 289, 1933-1937 (2000).
14. Morham, S.G. et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83, 473-482 (1995).
15. Dinchuk, J.E. et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378, 406-409 (1995).
16. Lim, H. et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91, 197-208 (1997).
17. Shimokawa, T., Kulmacz, R.J., DeWitt, D.L. & Smith, W.L. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J. Biol. Chem. 265, 20073-20076 (1990).
18. Yu, Y. et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J. Clin. Invest. 115, 986-995 (2005).
19. Nguyen, M. et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 390, 78-81 (1997).
20. Segi, E. et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem. Biophys. Res. Commun. 246, 7-12 (1998).
21. Smith, G.C. The pharmacology of the ductus arteriosus. Pharmacol. Rev. 50, 35-58 (1998).
22. Yuan, C., Rieke, C.J., Rimon, G., Wingerd, B.A. & Smith, W.L. Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci. USA 103, 6142-6147 (2006).
23. Trifan, O.C., Smith, R.M., Thompson, B.D. & Hla, T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin- independent mechanism. J. Biol. Chem. 274, 34141-34147 (1999).
24. Funk, C.D., Funk, L.B., Kennedy, M., Pong, A. & FitzGerald, G.A. Human platelet/erythroleukemia cell prostaglandin endoperoxide synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 5, 2304-2312 (1991).
25. Chen, W., Pawelek, T.R. & Kulmacz, R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 274, 20301-20306 (1999).
26. Cheng, Y. et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116, 1391-1399 (2006).
27. Campean, V., Theilig, F., Paliege, A., Breyer, M. & Bachmann, S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am. J. Physiol. Renal Physiol. 285, F19-F32 (2003).
28. Zhang, X., Morham, S.G., Langenbach, R. & Young, D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190, 451-59 (1999).
29. Szewczuk, L.M., Forti, L., Stivala, L.A. & Penning, T.M. Resveratrol is a peroxidase-mediated inactivatorof COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279, 22727-22737 (2004).
30. Selinsky, B.S., Gupta, K., Sharkey, C.T. & Loll, P.J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 40, 5172-5180 (2001).